Rekormon v lechenii anemii u onkologicheskikh bol'nykh
- Authors: Zhukov N.V1, Minenko S.V1, Popov A.Y.1, Ptushkin V.V1
-
Affiliations:
- Issue: No 2S (2008)
- Pages: 54-59
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/275764
- ID: 275764
Cite item
Full Text
Abstract
Обсуждается проблема анемии, возникающей на фоне лечения онкологических заболеваний, в т. ч. после химиотерапии. По данным литературы и результатам проведенного исследования, включавшего 15 пациентов с лимфопролиферативными заболеваниями, применение рекомбинантного эритропоэтина - эпоэтина бета (Рекормона) в режиме 30 000 МЕ один раз в неделю позволяет успешно увеличивать уровень гемоглобина, уменьшать потребность в заместительных трансфузиях и улучшать качество жизни больных, в т. ч. и получающих высокодозную химиотерапию с трансплантацией аутологичных клеток -предшественников гемопоэза.
Full Text
References
- Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15): 2293-306.
- Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(Suppl. 2):4-12.
- Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(Suppl. 2):13-19.
- Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40(15):2201-16.
- Cazzola M, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-93.
- Ayash LJ, Elias A, Hunt M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994;87:153-61.
- Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994;13:403-10.
- Baron F, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation (alloPBSCT) when started soon after engraftment. Haematologica 2003;88: 718-20.
- Beguin Y, Baron F, Fillet G. Influence of marrow activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 1998;83:1076-81.
- Beguin Y, Clemons GK, Oris R, et al. Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood 1991;77:868-73.
- Baron F, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation (alloPBSCT) when started soon after engraftment. Haematologica 2003;88.
- Hensel M, Egerer G, Schneeweiss A. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol 2002;13(2):209-17.
- Demetri GD, Kris M, Wade J, et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16: 3412-25.
- Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995;92:3717-20.
- Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
Supplementary files
